Apollomics announces changes in executive leadership team

Apollomics ( NASDAQ: APLM ) has announced an updated strategic focus for the clinical development of vebreltinib by focusing on NSCLC patients with Met Amplification, as well as changes to its executive leadership team . As a result of the updated strategic focus, and aligned with the Co.’s resource needs going forward, Sanjeev Redkar, Ph.

D., Co. co-founder and President, and Peony Yu, M.

D., CMO, are expected to transition to consulting roles in August. “We believe that the target selectivity and efficacy of vebreltinib against multiple tumor types demonstrates its high potential to treat a range of MET-altered tumors,” said Guo-Liang Yu, Ph.

D., Chairman and CEO. Apollomics now expects that its current capital resources will fund planned operations into the third quarter of 2025.

APLM +5.25% premarket to $0.2023.

More on Apollomics Seeking Alpha’s Quant Rating on Apollomics Historical earnings data for Apollomics Financial information for Apollomics.